News | PET Imaging | July 08, 2021

Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia

Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia

Getty Images


July 8, 2021 — Biogen and Eisai Co., Ltd. announced the U.S. Food and Drug Administration (FDA) has approved an updated label for Aduhelm (aducanumab-avwa) injection 100 mg/mL solution.

The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinical trials, as seen below (italics to note updated language).

Aduhelm is indicated for the treatment of Alzheimer’s disease. Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with Aduhelm. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

Alfred Sandrock, Jr., M.D., Ph.D., Head of Research and Development at Biogen, said, “Based on our ongoing conversations with prescribing physicians, FDA and patient advocates, we submitted this label update with the goal to further clarify the patient population that was studied across the three Aduhelm clinical trials that supported approval. We are committed to continue to listen to the community’s needs as clinical practice adapts to this important, first-in-class treatment option.”

The update clarifies the indication by emphasizing information about the disease stages studied in the Aduhelm clinical trials. Information about the population studied has been previously communicated by Biogen and Eisai, including in the companies’ statement of June 23, 2021.

See the full Prescribing Information.

Related Alzheimers' content:

FDA Grants Accelerated Approval for Alzheimer’s Drug Aduhelm

VIDEO: Researchers Use MRI to Predict Alzheimer's Disease

Brain Iron Accumulation Linked to Cognitive Decline in Alzheimer's Patients

Good Results for Alzheimer’s Imaging Agent

NIH Augments Large Scale Study of Alzheimer’s Disease Biomarkers

Alzheimer’s Association Launches New Website for IDEAS Study

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment


Related Content

News | Ultrasound Imaging

June 5, 2023 ‑ Mindray, a global leader and developer of healthcare solutions and technologies in patient monitoring ...

Time June 05, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

June 2, 2023 — Philips has entered into a collaboration with medical imaging company Polarean to advance the field of ...

Time June 02, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

June 2, 2023 — Ezra, the healthcare artificial intelligence (AI) startup transforming early cancer detection through ...

Time June 02, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

June 2, 2023 — The University of Minnesota and Te Herenga Waka—Victoria University of Wellington, NZ, have received ...

Time June 02, 2023
arrow
News | Point-of-Care Ultrasound (POCUS)

June 1, 2023 —Fujifilm Sonosite, Inc. has added to its leading portfolio of systems with the launch of Sonosite ST ...

Time June 01, 2023
arrow
Feature | Radiology Imaging | By Melinda Taschetta-Millane

It's been a fruitful month for itnonline.com! Here's a look at what ITN viewers found to be most interesting during the ...

Time June 01, 2023
arrow
News | Artificial Intelligence

May 31, 2023 — GE HealthCare announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning ...

Time May 31, 2023
arrow
News | Radiopharmaceuticals and Tracers

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
arrow
News | Radiology Business

May 30, 2023 — Strategic Radiology (SR) welcomed 23-radiologist Radiology Associates of Eugene, OR, to the national ...

Time May 30, 2023
arrow
News | Radiology Business

May 26, 2023 — Siemens Healthineers and CommonSpirit Health have agreed to acquire Block Imaging. This new acquisition ...

Time May 26, 2023
arrow
Subscribe Now